DENVER & BURLINGTON, N.C.--(BUSINESS WIRE)--National Jewish Health and Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) (LabCorp) have reached an agreement to collaborate in the development and commercialization of molecular diagnostic tests in support of personalized medicine. The collaboration combines National Jewish Health’s strengths in molecular diagnostics and respiratory, immune, and related diseases with LabCorp’s national leadership in personalized medicine and esoteric testing.
